Abstract: A freestanding thin film of nano-crystalline graphite is described, as well as a method of producing a freestanding thin film of nano-crystalline graphite including: providing a freestanding thin film of amorphous carbon, heating the freestanding thin film to a high temperature in an inert atmosphere or in a vacuum; and allowing the freestanding thin film to cool down, as a result of which a freestanding thin film of nano-crystalline graphite is formed. The films can be used, for example, as phase plates in a Transmission Electron Microscope.

Abstract: The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.

Abstract: The present invention relates to nucleic acids encoding peptides capable of binding to actin. The nucleic acids encoding the peptides are useful in methods for detecting actin in vitro or in living cells.

Abstract: A cloak server is used to analyze and control disclosure of user data by authenticating at least one of a user, an at least one client associated with the user, a source, a sink, and a third party. The cloak server receives user data transmitted by at least one of the at least one client and a source and associates the received user data with the user. The cloak server stores, seals, and unseals the received user data and is hardened such that the stored user data is not readable from outside the cloak server. The cloak server further generates, based at least in part on a first permissions indicator, a result by executing a computation on the stored user data, and transmits, based at least in part on a second permissions indicator, the result to at least one of the at least one client, and a sink.

Abstract: The present invention relates to a method of identifying a predisposition for developing posttraumatic stress disorder (PTSD) in a subject comprising assessing in a sample obtained from said subject the expression level of one or more genes selected from the FK506 binding protein 5 (FKBP5) gene, the signal transducer and activator of transcription (STAT5B) gene and the nuclear factor I/A (NFIA) gene, wherein a decrease in the expression level of said one or more genes as compared to the expression level of the corresponding gene(s) of a control is indicative of a predisposition for developing PTSD. Further, the invention relates to a method of identifying a compound capable of preventing or treating PTSD or capable of serving as a lead compound for developing a compound capable of preventing or treating PTSD and also to a method of selecting a therapy to prevent or treat PTSD.

Abstract: A method for encoding high dynamic range (HDR) images involves providing a lower dynamic range (LDR) image, generating a prediction function for estimating the values for pixels in the HDR image based on the values of corresponding pixels in the LDR image, and obtaining a residual frame based on differences between the pixel values of the HDR image and estimated pixel values. The LDR image, prediction function and residual frame can all be encoded in data from which either the LDR image of HDR image can be recreated.

Abstract: Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

Abstract: The present invention relates to a convertor for converting alternating movement to unidirectional movement, the convertor comprising an actuator for generating the alternating movement, the actuator being disposed to exert compressive and tensile forces on first and second members, the first said member having a positive Poisson's ratio and the second said member having a negative Poisson's ratio, and the first and second members being adapted for differential frictional engagement with a structure.

Abstract: The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.

Abstract: The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.

Abstract: The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNF? or TNF) treatment to asses the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNF? treatment.

Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.

Abstract: The present invention relates to a process for edge-halogenation of a graphene material; wherein the graphene material, which is selected from graphene, a graphene nanoribbon, a graphene molecule, or a mixture thereof, is reacted with a halogen-donor compound in the presence of a Lewis acid, so as to obtain an edge-halogenated graphene material.

Abstract: The present invention relates to a method of manufacturing an amorphous electrode material comprising the steps of: mixing an ionic liquid containing halide compound, nanostructures and precursors to form initially planar sheets of compounds of the halide and an element of the precursor to form a mixture; cooling the mixture to a temperature below ambient temperature, typically less than 3° C.; whereby the planar sheets are coated with the ionic liquid and curled to form microspheres of agglomerations of the curled planar sheets interconnected by the nanostructures. The invention further relates to an electrode material and to an interconnected network of electrode material.

Abstract: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.

Abstract: A computer system includes a database configured to receive a query and to produce a list of User IDs and an anonymization module. The anonymization module is configured to receive a list of user IDs in response to a query, the list of user IDs defining a true user count, generate a noisy user count of the list of user IDs, compare the true user count to a first threshold value stored in memory, compare the noisy user count to a second threshold value stored in memory, and output the noisy user count only if the true user count is greater than the first threshold value and the noisy user count is greater then the second threshold.

Abstract: A method of spectrally broadening light pulses includes the steps of providing the light pulses with a laser source, said light pulses having a pulse duration below 1 ps, in-coupling the light pulses into a hollow optical waveguide device, and spectrally broadening the light pulses propagating along the pulse guiding medium by subjecting them to a Raman nonlinearity via excitation of a Raman polarization having a first Raman period, wherein the optical waveguide device subjects the light pulses to anomalous group velocity dispersion which combines with the spectral broadening of the light pulses to result in a Raman-enhanced self-compression of the light pulses, and the light pulses further propagate along the optical waveguide device such that the Raman-enhanced self compression results in a further excitation of a Raman polarization having a second Raman period which is faster than the first Raman period.

Abstract: The present invention is directed to a method for producing artemisinin having the formula from dihydroartemisinic acid in a continuous flow reactor using singlet oxygen as well as to the continuous flow reactor for producing artemisinin.

Abstract: The present invention relates to a method for the fabrication of nanostructures, comprising the steps of: a) providing a substrate having a polycrystalline film on at least a surface thereof, wherein the polycrystalline film is a film having grain boundaries; and b) exposing the polycrystalline film to a vapor flux at a temperature equal to or above ambient temperature, wherein at least one element which is included in the vapor diffuses into the grain boundaries of the polycrystalline film resulting in growth of nanostructures at said grain boundaries. The invention further relates to a network of interconnected nanostructures, to a nanostructure, as well as to an apparatus for the fabrication of nanostructures and networks of interconnected nanostructures.

Abstract: The invention concerns a kit for preventing or treating oxidative stress in humans or animals by means of therapeutically active hydrogen molecules. The hydrogen molecules are formed by reacting a base metal with aqueous acids or bases and by reacting a saline hydride with water or aqueous acids.